Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

J. Trotman, SF. Barrington, D. Belada, M. Meignan, R. MacEwan, C. Owen, V. Ptáčník, A. Rosta, GR. Fingerle-Rowson, J. Zhu, T. Nielsen, D. Sahin, W. Hiddemann, RE. Marcus, A. Davies, PET investigators from the GALLIUM study,

. 2018 ; 19 (11) : 1530-1542. [pub] 20181008

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028158
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 30309758
DOI 10.1016/s1470-2045(18)30618-1
Knihovny.cz E-zdroje

BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET-CT responses after first-line immunochemotherapy in the GALLIUM study. METHODS: GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1-3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment. Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m2 on day 1 of each cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone (known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral administration), or six 28-day cycles with bendamustine, followed by maintenance antibody every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed progression-free survival, has been reported previously. This secondary analysis reports PET and CT-based responses at end-of-induction therapy and explains their relation with progression-free and overall survival outcomes in patients with available scans. As per protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with available PET facilities, and optional thereafter), acquired at baseline and end of induction (PET population), were assessed prospectively by investigators and an independent review committee (IRC) applying International Harmonisation Project (IHP) 2007 response criteria, and retrospectively by the IRC only applying current Lugano 2014 response criteria. IRC members (but not study investigators) were masked to treatment and clinical outcome when assessing response. The landmark analyses excluded patients who died or progressed (contrast enhanced CT-based assessment of progressive disease, or started next anti-lymphoma treatment) before or at end of induction. GALLIUM is registered at ClinicalTrials.gov, number NCT01332968. FINDINGS: 1202 patients were enrolled in GALLIUM between July 6, 2011, and Feb 4, 2014, of whom 595 were included in the PET population; 533 (IHP 2007; prospective analysis), and 508 (Lugano 2014; retrospective analysis) were analysed for progression-free survival (landmark analysis). At end of induction, 390 of 595 patients (65·5% [95% CI 61·6-69·4]) achieved PET complete response according to IHP 2007 criteria, and 450 (75·6% [95% CI 72·0-79·0]) obtained PET complete metabolic response according to Lugano 2014 criteria. With a median of 43·3 months of observation (IQR 36·2-51·8), 2·5-year progression-free survival from end of induction was 87·8% (95% CI 83·9-90·8) in PET complete responders and 72·0% (63·1-79·0) in non-complete responders according to IRC-assessed IHP 2007 criteria (hazard ratio [HR] 0·4, 95% CI 0·3-0·6, p<0·0001). According to Lugano 2014 criteria, 2·5-year progression-free survival in complete metabolic responders was 87·4% (95% CI 83·7-90·2) and in non-complete metabolic responders was 54·9% (40·5-67·3; HR 0·2, 95% CI 0·1-0·3, p<0·0001). INTERPRETATION: Our results suggest that PET is a better imaging modality than contrast-enhanced CT for response assessment after first-line immunochemotherapy in patients with follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed. FUNDING: F Hoffmann-La Roche.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028158
003      
CZ-PrNML
005      
20250617121313.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(18)30618-1 $2 doi
035    __
$a (PubMed)30309758
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Trotman, Judith $u Haematology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, NSW, Australia. Electronic address: judith.trotman@health.nsw.gov.au.
245    10
$a Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial / $c J. Trotman, SF. Barrington, D. Belada, M. Meignan, R. MacEwan, C. Owen, V. Ptáčník, A. Rosta, GR. Fingerle-Rowson, J. Zhu, T. Nielsen, D. Sahin, W. Hiddemann, RE. Marcus, A. Davies, PET investigators from the GALLIUM study,
520    9_
$a BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET-CT responses after first-line immunochemotherapy in the GALLIUM study. METHODS: GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1-3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment. Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m2 on day 1 of each cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone (known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral administration), or six 28-day cycles with bendamustine, followed by maintenance antibody every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed progression-free survival, has been reported previously. This secondary analysis reports PET and CT-based responses at end-of-induction therapy and explains their relation with progression-free and overall survival outcomes in patients with available scans. As per protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with available PET facilities, and optional thereafter), acquired at baseline and end of induction (PET population), were assessed prospectively by investigators and an independent review committee (IRC) applying International Harmonisation Project (IHP) 2007 response criteria, and retrospectively by the IRC only applying current Lugano 2014 response criteria. IRC members (but not study investigators) were masked to treatment and clinical outcome when assessing response. The landmark analyses excluded patients who died or progressed (contrast enhanced CT-based assessment of progressive disease, or started next anti-lymphoma treatment) before or at end of induction. GALLIUM is registered at ClinicalTrials.gov, number NCT01332968. FINDINGS: 1202 patients were enrolled in GALLIUM between July 6, 2011, and Feb 4, 2014, of whom 595 were included in the PET population; 533 (IHP 2007; prospective analysis), and 508 (Lugano 2014; retrospective analysis) were analysed for progression-free survival (landmark analysis). At end of induction, 390 of 595 patients (65·5% [95% CI 61·6-69·4]) achieved PET complete response according to IHP 2007 criteria, and 450 (75·6% [95% CI 72·0-79·0]) obtained PET complete metabolic response according to Lugano 2014 criteria. With a median of 43·3 months of observation (IQR 36·2-51·8), 2·5-year progression-free survival from end of induction was 87·8% (95% CI 83·9-90·8) in PET complete responders and 72·0% (63·1-79·0) in non-complete responders according to IRC-assessed IHP 2007 criteria (hazard ratio [HR] 0·4, 95% CI 0·3-0·6, p<0·0001). According to Lugano 2014 criteria, 2·5-year progression-free survival in complete metabolic responders was 87·4% (95% CI 83·7-90·2) and in non-complete metabolic responders was 54·9% (40·5-67·3; HR 0·2, 95% CI 0·1-0·3, p<0·0001). INTERPRETATION: Our results suggest that PET is a better imaging modality than contrast-enhanced CT for response assessment after first-line immunochemotherapy in patients with follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed. FUNDING: F Hoffmann-La Roche.
650    _2
$a senioři $7 D000368
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a protinádorové látky imunologicky aktivní $x aplikace a dávkování $x škodlivé účinky $7 D000074322
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a klinické zkoušky, fáze III jako téma $7 D017326
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x škodlivé účinky $x metody $7 D007167
650    _2
$a folikulární lymfom $x diagnostické zobrazování $x imunologie $x mortalita $x terapie $7 D008224
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    12
$a pozitronová emisní tomografie $7 D049268
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a prospektivní studie $7 D011446
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rituximab $x aplikace a dávkování $x škodlivé účinky $7 D000069283
650    _2
$a časové faktory $7 D013997
650    _2
$a počítačová rentgenová tomografie $7 D014057
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Barrington, Sally F. $u King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, UK. $7 xx0333115
700    1_
$a Belada, David $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Králové, Hradec Králové, Czech Republic; Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Meignan, Michel $u LYSA Imaging, Hôpital Henri Mondor and Université Paris Est Créteil, Créteil, France.
700    1_
$a MacEwan, Robert $u University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada.
700    1_
$a Owen, Carolyn $u Foothills Medical Centre and Tom Baker Cancer Centre, Calgary, AB, Canada.
700    1_
$a Ptáčník, Václav $u Institute of Nuclear Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Rosta, András $u Department of Medicine, National Institute of Oncology, Budapest, Hungary.
700    1_
$a Fingerle-Rowson, Günter R $u Pharma Development Clinical Oncology, F Hoffmann-La Roche, Basel, Switzerland.
700    1_
$a Zhu, Jiawen $u Pharma Development Biometrics Biostatistics, F Hoffmann-La Roche, New York, NY, USA.
700    1_
$a Nielsen, Tina $u Pharma Development Clinical Oncology, F Hoffmann-La Roche, Basel, Switzerland.
700    1_
$a Sahin, Deniz $u Pharma Development Clinical Oncology, F Hoffmann-La Roche, Basel, Switzerland.
700    1_
$a Hiddemann, Wolfgang $u Department of Medicine III, LMU, University Hospital LMU, Munich, Germany.
700    1_
$a Marcus, Robert E $u Department of Haematology, Kings College Hospital, London, UK.
700    1_
$a Davies, Andrew $u Cancer Research UK Centre, University of Southampton, Southampton, UK.
710    2_
$a PET investigators from the GALLIUM study
773    0_
$w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 19, č. 11 (2018), s. 1530-1542
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30309758 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20250617121305 $b ABA008
999    __
$a ok $b bmc $g 1433307 $s 1066618
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 11 $d 1530-1542 $e 20181008 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace